Management of Elderly Patients with Rapidly Progressive Glomerulonephritis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376127" target="_blank" >RIV/00216208:11110/18:10376127 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/18:10376127
Result on the web
<a href="https://doi.org/10.1159/000485368" target="_blank" >https://doi.org/10.1159/000485368</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000485368" target="_blank" >10.1159/000485368</a>
Alternative languages
Result language
angličtina
Original language name
Management of Elderly Patients with Rapidly Progressive Glomerulonephritis
Original language description
Background: Rapidly progressive glomerulonephritis (RPGN) is characterized by a rapid deterioration of renal function and by extracapillary proliferation in >50% of glomeruli. The most common type of RPGN is "pauci-immune" glomerulonephritis caused by anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV). Summary: The incidence of AAV increases with age and pauci-immune glomerulonephritis is the most common diagnosis found in renal biopsies in the elderly population. Age was identified as an independent negative risk factor for both death and end-stage renal disease in AAV, and the mortality of older patients was uniformly higher than in younger patients in all retrospective studies. Early diagnosis may be difficult particularly in elderly patients with renal-limited disease but is important for the good outcome of the patients. Immunosuppressive treatment options include cyclophosphamide or rituximab combined with corticosteroids with or without plasma exchange in case of severe disease. Data from randomized trials are completely missing for patient aged >75 years. Based on retrospective studies, elderly patients seem to respond to immunosuppressive drugs just as younger patients are able to, but they are at a higher risk of adverse events. Key Messages: RPGN is relatively common in the elderly patients. Immunosuppressive treatment in older patients with AAV or RPGN may be useful but needs to be strictly individualized with all the risks taken into consideration. Further studies are needed to examine the role of novel therapeutic options in the elderly population with RPGN.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Purification
ISSN
0253-5068
e-ISSN
—
Volume of the periodical
45
Issue of the periodical within the volume
1-3
Country of publishing house
CH - SWITZERLAND
Number of pages
5
Pages from-to
213-217
UT code for WoS article
000430844600033
EID of the result in the Scopus database
2-s2.0-85041613361